Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1994-12-09
1997-10-28
Chambers, Jasemine C.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
4352402, 4353201, 4351723, 435 695, 4241841, 4242771, A61K 4800, A61K 3900, C12N 500
Patent
active
056815620
ABSTRACT:
A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen gene product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.
REFERENCES:
Rosenberg, Steven A. "The Immunotherapy and Gene Therapy of Cancer." J. Clin. Oncology 10:180-199 (1992).
Russell, Stephen J. "Lymphokine Gene Therapy for Cancer." Immunology Today. 11:196-200 (1990).
Wakabayashi et al. Cytoxic T-lymphocyte induced by syngeneic mouse melanoma cells recognize human melanomas. Nature 294, vol. 294, 748-750, 1981.
Gansbacher, Bernd et al., "Interleukin 2 Gene Transfer into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity", J. Exp. Med. 90:1237-1224 (1990).
Gabrilove, Janice l. and Jakubowski, Ann "Hematopoietic Growth Factors: Biology and Clinical Application". J. of the National Cancer Inst. Monographs. 10:73-77 (1990).
Sarna, Gregory et al., "A Pilot Study of Intralymphatic Interleukin-2. II. Clinical and Biological Effects". J. Biol. Response Modifiers. 9:81-86 (1990).
Hoover, H.C. Jr. et al., "Delayed Cutaneous Hypersensitivity to Autologous Tumor Cells in Colorectal Cancer Patients Immunized With the Autologous Tumor Cell": Bacillus calmette-Guerin Vaccine Cancer Res. 44:1671-1676 (1984).
Bubenik, J. et al., "Immunotherapy of Cancer using Local Administration of Lymphpoid Cells Transformed by IL-2 cDNA and Constitutively Producing IL-2". Immunology Letters. 23:287-292 (1989/1990).
Borden, Ernest C., and Sondel, Paul m., "Lympokines and Cytokines as Cancer". 65:800-814 (1990).
Rosenberg, Steven A. et al., "New Approaches to the Immunotherapy of Cancer Using Interleukin-2". Annals of Internal Medicine. 108:853-864 (1988).
Li Xu, et al., "Factors Affecting Long-Term Stability of Moloney Murine Leukemia Virus-Based Vectors". Virology 171:331-341 (1989).
Gansbacher. Bernd, et al., "Retroviral Vector-Mediated .tau.Interferon Gene Transfer into Tumor Cells Generates Potent and Antitumor Immunity." Cancer Research 50:7820-7825 (1990).
Fearon, Eric R. et al., "Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response." Cell 60:397-403 (1990).
Gandolfi, L. et al., "Intratumoral Echo-guided Injection of INterleukin-2 and Lymphokine-Activated Killer Cells in Hepatorcellular Carcinom." Hepato-gastroenterol 36:352-356 (1989).
Watanabe, Yoshihiko et al., "Exogenous Expression of Mouse Interferon .tau.cDNA in Mouse Neuroblastoma C1300 Cells Results in Reduced Tumorigenicity by Augmented Anti-Tumor Immunity." Proc. Natl. Acad. Sci. USA. 86:9456-9460 (1989).
Pizza, G. et al., "Intra-Lymphatic Administration of Interleukin-2 (IL-2) in Cancer Patients: A Pilot Study." Lympokine Research 7:45-48 (1988).
Lotze, Michael T. et al., "High-Dose Recombinant Interleukin 2 in the Treatment of Patients with Disseminated Cancer." JAMA 256:3117-3124 (1986).
Lotze, Michael T. et al., "Mechanisms of Immunologic Antitumor Therapy: Lession from the Laboratory and Clinical Applications." Human Immunology 28:198-207 (1990).
Schreiber, Hans. "Tumor Immunology." Fundamental Immunology, Second Edition. 923-942 (1989).
Peace, David J. et al., "T Cell Recognition of Transforming Proteins Encoded by Mutated ras Proto-Oncogenes." J. Immunology. 146:2059-2065 (1991).
Bubenik, J. et al., "Local Administration of Cells Containing an Inserted IL-2 Gene and Producing IL-2 Inhibits Growth of Human Tumors in Nu/Nu Mice." Immunology Letters. 19:279-282 (1988).
Tepper, Robert I. et al., "Murine Interleukia-4 Displays Potent Anti-tumor Activity on Vivo." Cell 57:503-512 (1989).
Borrelli, Emiliana, et al., "Targeting of an Inducible Toxic Phenotype in Animal Cells." Proc. Natl. Acad. Sci. USA. 85:7572-7576 (1988).
Lotze, Michael T. and Finn, Olivera J., "Recent Advances in Cellular Immunology: Implications for Immunity to Cancer." Immunotherapy Today 11:190-193 (1990).
Rosenberg, Steven et al., "Gene Transfer Into Humans-Immunotherapy of Patients with Advances Melanoma, Using Tumor-Infiltrating Lympocytes Modified by Retroviral Gene Transduction." New England J. Medicine. 323:570-578 (1990).
Ogura, Hiromi et al., "Implantation of Genetically Manipulated Fibroblasts into Mice as Antitumor .alpha.-Interferon Therapy." Cancer Research 50:5102-5106 (1990).
Cohen, J. Science 262:841-843 5 Nov. 1993.
Fakhrai Habib
Friedman Theodore
Gage Fred H.
Royston Ivor
Sobol Robert E.
Chambers Jasemine C.
Hauda Karen Marie
Sidney Kimmel Cancer Center
LandOfFree
Lymphokine gene therapy of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lymphokine gene therapy of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphokine gene therapy of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1024259